The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity

Journal of Biological Chemistry

Volumn 288, Issue 47, 2013, Pages 34181-34189

  Cao, Biyin ^a   Li, Jie ^a   Zhu, Jingyu ^a   Shen, Mingyun ^a   Han, Kunkun ^a   Zhang, Zubin ^a   Yu, Yang ^a   Wang, Yali ^a   Wu, Depei ^a   Chen, Suning ^a   Sun, Aining ^a   Tang, Xiaowen ^a   Zhao, Yun ^a   Qiao, Chunhua ^a   Hou, Tingjun ^a   Mao, Xinliang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL-CYCLE ARREST; COMPUTER MODELING; COORDINATE BONDS; HEMATOLOGICAL MALIGNANCIES; HISTONE DEACETYLASES; MECHANISTIC STUDIES; MOLECULAR MECHANISM; OXYGEN AND NITROGENS;

ACETYLATION; CELL DEATH; CHLORINE COMPOUNDS; DISEASES; DRUG PRODUCTS; ENZYMES; HYDROGEN BONDS;

PROTEINS;

ALPHA TUBULIN; ASPARTIC ACID; CLIOQUINOL; COPPER CHLORIDE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE H3; HYDROXYL GROUP; NITROGEN; OXYGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; ZINC CHLORIDE; ZINC ION;

ACETYLATION; APOPTOSIS; ARTICLE; CHEMICAL BOND; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYDROGEN BOND; LEUKEMIA CELL; MOLECULAR DOCKING; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CLIOQUINOL; COMPUTER MODELING; ENZYME INHIBITORS; HISTONE DEACETYLASE; MULTIPLE MYELOMA;

ANTIPRURITICS; APOPTOSIS; CHLORIDES; CLIOQUINOL; DOWN-REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; K562 CELLS; LEUKEMIA; MALE; MOUTHWASHES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; U937 CELLS; ZINC COMPOUNDS;

EID: 84888329493     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.472563     Document Type: Article

References (48)

1. Rodríguez-Paredes, M., and Esteller, M. (2011) Cancer epigenetics reaches mainstream oncology. Nat. Med. 17, 330-339
2. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., and Mann, M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840
3. Yang, X. J., and Seto, E. (2007) HATs and HDACs. From structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310-5318
4. Gallinari, P., Di Marco, S., Jones, P., Pallaoro, M., and Steinkühler, C. (2007) HDACs, histone deacetylation and gene transcription. From molecular biology to cancer therapeutics. Cell Res. 17, 195-211
5. Conti, C., Leo, E., Eichler, G. S., Sordet, O., Martin, M. M., Fan, A., Aladjem, M. I., and Pommier, Y. (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 70, 4470-4480
6. Lane, A. A., and Chabner, B. A. (2009) Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468
7. Condorelli, F., Gnemmi, I., Vallario, A., Genazzani, A. A., and Canonico, P. L. (2008) Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol. 153, 657-668
8. Mao, X., Hou, T., Cao, B., Wang, W., Li, Z., Chen, S., Fei, M., Hurren, R., Gronda, M., Wu, D., Trudel, S., and Schimmer, A. D. (2011) The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases. In vitro and in silico evidence. Mol. Pharmacol. 79, 672-680
9. Chen, J. S., and Faller, D. V. (2005) Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J. Cell. Physiol. 202, 87-99
10. Zhang, F., Shi, Y., Wang, L., and Sriram, S. (2011) Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One 6, e16795
11. Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza-Delgado, I., Nademanee, A., Forman, S. J., Gandara, D., and Newman, E. (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 1198-1203
12. Piekarz, R., and Bates, S. (2004) A review ofdepsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289-2298
13. Chen, P. C., Patil, V., Guerrant, W., Green, P., and Oyelere, A. K. (2008) Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 16, 4839-4853
14. Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., McLean, T. H., Bochkarev, A., Plotnikov, A. N., Vedadi, M., and Arrowsmith, C. H. (2008) Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355-11363
15. Mao, X., and Schimmer, A. D. (2008) The toxicology ofclioquinol. Toxicol. Lett. 182, 1-6
16. Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., and Dou, Q. P. (2005) Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 7, R897-908
17. Mao, X., Li, X., Sprangers, R., Wang, X., Venugopal, A., Wood, T., Zhang, Y., Kuntz, D. A., Coe, E., Trudel, S., Rose, D., Batey, R. A., Kay, L. E., and Schimmer, A. D. (2009) Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia 23, 585-590
18. Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P., and Dou, Q. P. (2007) Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 67, 1636-1644
19. Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H. E., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., So, A., and Liu, J. O. (2010) Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J. Natl. Cancer Inst. 102, 1855-1873
20. Li, X., Wood, T. E., Sprangers, R., Jansen, G., Franke, N. E., Mao, X., Wang, X., Zhang, Y., Verbrugge, S. E., Adomat, H., Li, Z. H., Trudel, S., Chen, C., Religa, T. L., Jamal, N., Messner, H., Cloos, J., Rose, D. R., Navon, A., Guns, E., Batey, R. A., Kay, L. E., and Schimmer, A. D. (2010) Effect of noncompetitive proteasome inhibition on bortezomib resistance. J. Natl. Cancer Inst. 102, 1069-1082
21. Bareggi, S. R., and Cornelli, U. (2012) Clioquinol. Review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci. Ther. 18, 41-46
22. Yu, H., Zhou, Y., Lind, S. E., and Ding, W. Q. (2009) Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 417, 133-139
23. Chen, H. L., Chang, C. Y., Lee, H. T., Lin, H. H., Lu, P. J., Yang, C. N., Shiau, C. W., and Shaw, A. Y. (2009) Synthesis and pharmacological exploitation of clioquinol-derived copper-binding apoptosis inducers triggering reactive oxygen species generation and MAPK pathway activation. Bioorg. Med. Chem. 17, 7239-7247
24. Schimmer, A. D. (2011) Clioquinol. A novel copper-dependent and independent proteasome inhibitor. Curr. Cancer Drug Targets 11, 325-331
25. Mao, X., Liang, S. B., Hurren, R., Gronda, M., Chow, S., Xu, G. W., Wang, X., Beheshti Zavareh, R., Jamal, N., Messner, H., Hedley, D. W., Datti, A., Wrana, J. L., Zhu, Y., Shi, C. X., Lee, K., Tiedemann, R., Trudel, S., Stewart, A. K., and Schimmer, A. D. (2008) Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 112, 760-769
26. Mao, X., Cao, B., Wood, T. E., Hurren, R., Tong, J., Wang, X., Wang, W., Li, J., Jin, Y., Sun, W., Spagnuolo, P. A., MacLean, N., Moran, M. F., Datti, A., Wrana, J., Batey, R. A., and Schimmer, A. D. (2011) A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood 117, 1986-1997
27. Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C, Ho, J. D., Jennings, A. J., Luong, C, Arvai, A., Buggy, J. J., Chi, E., Tang, J., Sang, B. C, Verner, E., Wynands, R., Leahy, E. M., Dougan, D. R., Snell, G., Navre, M., Knuth, M. W., Swanson, R. V., McRee, D. E., and Tari, L. W. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325-1334
28. Case, D. A., Cheatham, T. E., 3rd, Darden, T., Gohlke, H., Luo, R., Merz, K. M., Jr., Onufriev, A., Simmerling, C, Wang, B., and Woods, R. J. (2005) The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688
29. Bayly, C. I., Cieplak, P., Cornell, W. D., and Kollman, P. A. (1993) A wellbehaved electrostatic potential based method using charge restraints for deriving atomic charges. The Resp model. J. Phys. Chem. 97, 10269-10280
30. Duan, Y., Wu, C, Chowdhury, S., Lee, M. C, Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., Caldwell, J., Wang, J., and Kollman, P. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 24, 1999-2012
31. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., and Case, D. A. (2004) Development and testing of a general amber force field. J. Comput. Chem. 25, 1157-1174
32. Mao, X., Stewart, A. K., Hurren, R., Datti, A., Zhu, X., Zhu, Y., Shi, C, Lee, K., Tiedemann, R., Eberhard, Y., Trudel, S., Liang, S., Corey, S. J., Gillis, L. C, Barber, D. L., Wrana, J. L., Ezzat, S., and Schimmer, A. D. (2007) A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood 110, 4047-4054
33. Mercurio, C, Minucci, S., and Pelicci, P. G. (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 62, 18-34
34. Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev. Drug. Discov. 5, 769-784
35. Claus, R., and Lübbert, M. (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22, 6489-6496
36. Melnick, A., and Licht, J. D. (2002) Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9, 322-332
37. Marquard, L., Gjerdrum, L. M., Christensen, I. J., Jensen, P. B., Sehested, M., and Ralfkiaer, E. (2008) Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53, 267-277
38. Wood, T. E., Dalili, S., Simpson, C. D., Sukhai, M. A., Hurren, R., Anyiwe, K., Mao, X., Suarez Saiz, F., Gronda, M., Eberhard, Y., MacLean, N., Ketela, T., Reed, J. C, Moffat, J., Minden, M. D., Batey, R. A., and Schimmer, A. D. (2010) Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol. Cancer Ther. 9, 246-256
39. Hu, J., and Colburn, N. H. (2005) Histone deacetylase inhibition downregulates cyclin D1 transcription by inhibiting nuclear factor-B/p65 DNA binding. Mol. Cancer Res. 3, 100-109
40. Hu, X., Bryington, M., Fisher, A. B., Liang, X., Zhang, X., Cui, D., Datta, I., and Zuckerman, K. S. (2002) Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J. Biol. Chem. 277, 16528-16537
41. Zhai, S., Yang, L., Cui, Q. C, Sun, Y., Dou, Q. P., and Yan, B. (2010) Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J. Biol. Inorg Chem. 15, 259-269
42. Rohde, W., Mikelens, P., Jackson, J., Blackman, J., Whitcher, J., and Levinson, W. (1976) Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus. Antimicrob. Agents. Chemother. 10, 234-240
43. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P. (1999) Structuresofahistone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193
44. Lagger, G., Doetzlhofer, A., Schuettengruber, B., Haidweger, E., Simboeck, E., Tischler, J., Chiocca, S., Suske, G., Rotheneder, H., Wintersberger, E., and Seiser, C. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 23, 2669-2679
45. Tang, Y., Zhao, W., Chen, Y., Zhao, Y., and Gu, W. (2008) Acetylation is indispensable for p53 activation. Cell 133, 612-626
46. Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., and Gu, W. (2004) Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 101, 2259-2264
47. Du, T., Filiz, G., Caragounis, A., Crouch, P. J., and White, A. R. (2008) Clioquinol promotes cancer cell toxicity through tumor necrosis factor a release from macrophages. J. Pharmacol. Exp. Ther. 324, 360-367
48. Kikuchi, J., Wada, T., Shimizu, R., Izumi, T., Akutsu, M., Mitsunaga, K., Noborio-Hatano, K., Nobuyoshi, M., Ozawa, K., Kano, Y., and Furukawa, Y. (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116, 406-417